Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers Journal Article
| Authors: | Hyman, D. M.; Zhou, Q.; Arnold, A. G.; Grisham, R. N.; Iasonos, A.; Kauff, N. D.; Spriggs, D. |
| Article Title: | Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers |
| Abstract: | Objective: To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas. Methods: A single-institution retrospective analysis of platinum-resistant patients characterized for the presence or absence of known deleterious BRCA mutations. Patients received topotecan at a dose and schedule determined by their treating physician (five day or weekly). Response rate and progression-free survival (PFS) were assessed. Results: A total of 50 patients (9 BRCA+, 41 BRCA-) were treated with topotecan. Both groups were well balanced in terms of age, stage, grade, and number of prior therapies. All patients had high-grade serous carcinoma. The clinical benefit rate in BRCA+ and BRCA- patients was 0% and 26.8% (6 PRs, 6 SDs), respectively (p = 0.18). Median PFS in BRCA+ and BRCA- pts was 1.7 months (95% CI: 1.0-2.8 months) and 2.5 months (95%CI: 1.9-2.8 months), respectively (p = 0.057). Median time to best response was 1.9 months, and median response duration 2.6 months. Conclusions: This analysis in a heavily pretreated cohort of patients fails to support the superiority of topotecan in BRCA+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Further study of this class of agents, specifically in less heavily-pretreated patients, may still be warranted. © 2011 Elsevier Inc. All rights reserved. |
| Keywords: | adult; cancer chemotherapy; controlled study; treatment response; aged; disease-free survival; middle aged; primary tumor; retrospective studies; gene mutation; major clinical study; gene deletion; mutation; drug efficacy; treatment duration; cancer patient; topotecan; cancer staging; ovarian cancer; ovarian neoplasms; progression free survival; peritoneum cancer; peritoneal neoplasms; cohort analysis; drug resistance, neoplasm; brca1 protein; retrospective study; genes, brca1; genes, brca2; ovary carcinoma; physician; platinum; uterine tube carcinoma; fallopian tube neoplasms; brca; topoisomerase i inhibitors |
| Journal Title: | Gynecologic Oncology |
| Volume: | 123 |
| Issue: | 2 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-11-01 |
| Start Page: | 196 |
| End Page: | 199 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2011.07.019 |
| PROVIDER: | scopus |
| PUBMED: | 21855118 |
| PMCID: | PMC3677700 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 9 December 2011" - "CODEN: GYNOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work